NO834349L - Lupusproevemetode og preparater for gjennomfoering derav - Google Patents

Lupusproevemetode og preparater for gjennomfoering derav

Info

Publication number: NO834349L
Authority: NO; Norway
Prior art keywords: approx; liposomes; phosphatidylcholine; liposome; phosphatidic acid
Prior art date: 1982-03-26

Application number

NO834349A

Other languages

English (en)

Norwegian (no)

Inventor

Andrew Stuart Janoff

Marc Jeffrey Ostro

Allan L Weiner

Gerald Weissmann

James R Seibold

Original Assignee

Liposome Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-03-26

Filing date

1983-11-25

Publication date

1983-11-25

1983-11-25 Application filed by Liposome Co Inc filed Critical Liposome Co Inc

1983-11-25 Publication of NO834349L publication Critical patent/NO834349L/no

Links

238000002360 preparation method Methods 0.000 title claims description 34
206010025135 lupus erythematosus Diseases 0.000 title description 11
238000010998 test method Methods 0.000 title description 2
239000002502 liposome Substances 0.000 claims description 110
210000002966 serum Anatomy 0.000 claims description 46
238000000034 method Methods 0.000 claims description 39
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 33
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 30
150000002632 lipids Chemical class 0.000 claims description 29
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 28
239000000427 antigen Substances 0.000 claims description 24
102000036639 antigens Human genes 0.000 claims description 24
108091007433 antigens Proteins 0.000 claims description 24
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 20
GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 16
230000008859 change Effects 0.000 claims description 15
BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims description 14
235000012000 cholesterol Nutrition 0.000 claims description 14
150000001768 cations Chemical class 0.000 claims description 12
230000001687 destabilization Effects 0.000 claims description 10
229940087168 alpha tocopherol Drugs 0.000 claims description 9
-1 calcium cations Chemical class 0.000 claims description 9
229960000984 tocofersolan Drugs 0.000 claims description 9
239000002076 α-tocopherol Substances 0.000 claims description 9
235000004835 α-tocopherol Nutrition 0.000 claims description 9
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 8
229910001425 magnesium ion Inorganic materials 0.000 claims description 8
239000000725 suspension Substances 0.000 claims description 8
238000001514 detection method Methods 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
230000000087 stabilizing effect Effects 0.000 claims description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 6
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 6
239000003283 colorimetric indicator Substances 0.000 claims description 6
RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims description 6
229940093541 dicetylphosphate Drugs 0.000 claims description 6
239000011777 magnesium Substances 0.000 claims description 6
229910052749 magnesium Inorganic materials 0.000 claims description 6
150000003431 steroids Chemical class 0.000 claims description 6
239000003963 antioxidant agent Substances 0.000 claims description 5
230000003078 antioxidant effect Effects 0.000 claims description 5
235000006708 antioxidants Nutrition 0.000 claims description 5
230000015572 biosynthetic process Effects 0.000 claims description 5
150000001793 charged compounds Chemical class 0.000 claims description 5
239000003960 organic solvent Substances 0.000 claims description 5
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims description 4
239000011575 calcium Substances 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
229910052792 caesium Inorganic materials 0.000 claims description 3
229910001424 calcium ion Inorganic materials 0.000 claims description 3
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
230000004044 response Effects 0.000 claims description 3
230000004941 influx Effects 0.000 claims description 2
OPVZUEPSMJNLOM-ZCXUNETKSA-N (1-hexadecanoyloxy-3-phosphonooxypropan-2-yl) (z)-octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC OPVZUEPSMJNLOM-ZCXUNETKSA-N 0.000 claims 3
239000006185 dispersion Substances 0.000 claims 2
229910021645 metal ion Inorganic materials 0.000 claims 2
239000003381 stabilizer Substances 0.000 claims 2
125000001020 α-tocopherol group Chemical group 0.000 claims 2
238000009835 boiling Methods 0.000 claims 1
229910052791 calcium Inorganic materials 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
159000000001 potassium salts Chemical class 0.000 claims 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 35
238000012360 testing method Methods 0.000 description 25
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
239000002253 acid Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000008346 aqueous phase Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
206010039710 Scleroderma Diseases 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
210000004940 nucleus Anatomy 0.000 description 4
230000035699 permeability Effects 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
125000000129 anionic group Chemical group 0.000 description 3
230000003460 anti-nuclear Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000002405 diagnostic procedure Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
239000002904 solvent Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
208000006379 syphilis Diseases 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000004520 agglutination Effects 0.000 description 2
239000011324 bead Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
229920001971 elastomer Polymers 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
159000000002 lithium salts Chemical class 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
150000003839 salts Chemical group 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
241000894007 species Species 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
YCLWEYIBFOLMEM-AGIMVQGUSA-N 4,5-dihydrocortisone Chemical compound C1C(=O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC21 YCLWEYIBFOLMEM-AGIMVQGUSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
238000000846 Bartlett's test Methods 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000003250 Mixed connective tissue disease Diseases 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
102000011931 Nucleoproteins Human genes 0.000 description 1
108010061100 Nucleoproteins Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
240000003834 Triticum spelta Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000003172 anti-dna Effects 0.000 description 1
230000009833 antibody interaction Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000003012 bilayer membrane Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
NCMHKCKGHRPLCM-UHFFFAOYSA-N caesium(1+) Chemical compound [Cs+] NCMHKCKGHRPLCM-UHFFFAOYSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229940006165 cesium cation Drugs 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
230000006870 function Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052816 inorganic phosphate Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910000000 metal hydroxide Inorganic materials 0.000 description 1
150000004692 metal hydroxides Chemical class 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
239000000693 micelle Substances 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
125000001394 octadec-9-enoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
208000008423 pleurisy Diseases 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
BUKHSQBUKZIMLB-UHFFFAOYSA-L potassium;sodium;dichloride Chemical compound [Na+].[Cl-].[Cl-].[K+] BUKHSQBUKZIMLB-UHFFFAOYSA-L 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000004321 preservation Methods 0.000 description 1
REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
229960000244 procainamide Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000003335 steric effect Effects 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
239000002691 unilamellar liposome Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Rehabilitation Therapy (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Rheumatology (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

NO834349A 1982-03-26 1983-11-25 Lupusproevemetode og preparater for gjennomfoering derav NO834349L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36238282A	1982-03-26	1982-03-26
US41024982A	1982-08-23	1982-08-23

Publications (1)

Publication Number	Publication Date
NO834349L true NO834349L (no)	1983-11-25

Family

ID=27001661

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO834349A NO834349L (no)	1982-03-26	1983-11-25	Lupusproevemetode og preparater for gjennomfoering derav

Country Status (5)

Country	Link
JP (1)	JPS59500529A (fr)
AU (1)	AU1510183A (fr)
DK (1)	DK541883A (fr)
NO (1)	NO834349L (fr)
WO (1)	WO1983003473A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4957735A (en) *	1984-06-12	1990-09-18	The University Of Tennessee Research Corporation	Target-sensitive immunoliposomes- preparation and characterization
US4865970A (en) *	1986-02-28	1989-09-12	Hoffmann-La Roche Inc.	Method of detecting ribosomal protein antibodies in systemic lupus erythematosus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4193983A (en) *	1978-05-16	1980-03-18	Syva Company	Labeled liposome particle compositions and immunoassays therewith
US4255411A (en) *	1978-11-27	1981-03-10	Damon Corporation	Process of determining an immunogenic substance by competition with an antibody in a microcapsule
US4372745A (en) *	1979-12-19	1983-02-08	Electro-Nucleonics, Inc.	Chemical luminescence amplification substrate system for immunochemistry involving microencapsulated fluorescer
US4342826A (en) *	1980-02-04	1982-08-03	Collaborative Research, Inc.	Immunoassay products and methods

1983
- 1983-03-24 JP JP58501479A patent/JPS59500529A/ja active Pending
- 1983-03-24 WO PCT/US1983/000420 patent/WO1983003473A1/fr not_active Ceased
- 1983-03-24 AU AU15101/83A patent/AU1510183A/en not_active Abandoned
- 1983-11-25 NO NO834349A patent/NO834349L/no unknown
- 1983-11-25 DK DK541883A patent/DK541883A/da not_active Application Discontinuation

Also Published As

Publication number	Publication date
JPS59500529A (ja)	1984-03-29
AU1510183A (en)	1983-10-24
DK541883D0 (da)	1983-11-25
DK541883A (da)	1983-11-25
WO1983003473A1 (fr)	1983-10-13

Publication	Publication Date	Title
US4564599A (en)	1986-01-14	Liposome composition for lupus assay
US4668638A (en)	1987-05-26	Liposome composition for lupus assay
Haxby et al.	1968	Immune response of a liposomal model membrane.
Carayon et al.	2011	Proteolipidic composition of exosomes changes during reticulocyte maturation
Elovson et al.	1988	Plasma very low density lipoproteins contain a single molecule of apolipoprotein B
US4704355A (en)	1987-11-03	Assay utilizing ATP encapsulated within liposome particles
FI81914C (fi)	1990-12-10	Lipidvesikel innehaollande detekterbart maerkningsaemne och dess anvaendning vid analys.
Inoue et al.	1974	Effect of exogenous lysolecithin of liposomal membranes its relation to membrane fluidity
Hope et al.	1981	The role of nonbilayer lipid structures in the fusion of human erythrocytes induced by lipid fusogens
Ramm et al.	1980	Life-span and size of the trans-membrane channel formed by large doses of complement
Miyamoto et al.	1971	Preparation and characteristics of lipid vesicles
Lachmann et al.	1970	Complement-mediated lysis of liposomes produced by thereactive lysis' procedure
Alving et al.	1977	Immune reactivities of antibodies against glycolipids—I: Properties of anti-galactocerebroside antibodies purified by a novel technique of affinity binding to liposomes
Edidin et al.	1977	Diffusion rates of cell surface antigens of mouse-human heterokaryons. I. Analysis of the population.
JP2021101705A (ja)	2021-07-15	赤血球タンパク質を生産するための方法
Abeywardena et al.	1983	Lipid-protein interactions of reconstituted membrane-associated adenosinetriphosphatases. Use of a gel-filtration procedure to examine phospholipid-activity relationships
US4185963A (en)	1980-01-29	Method for determining lipids in blood serum
CA1201382A (fr)	1986-03-04	Methode de depistage du lupus et compose a cet effet
AU1510183A (en)	1983-10-24	Lupus assay method and compositions
JP2577930B2 (ja)	1997-02-05	抗ストレプトリジンｏの新規測定法
Farias et al.	1995	Differential effect of triiodothyronine and thyroxine on the liposomal membrane in liquid-crystalline and gel state
WO1992007959A1 (fr)	1992-05-14	Procede de dosage immunologique lytique homogene sur membrane utilisant des formulations de liposomes sensibles au contact
Harris	1971	The proteins released from intact erythrocyte ghosts' at low ionic strength
US6015716A (en)	2000-01-18	Detection of endotoxin levels in liposomes, lipid bilayers and lipid complexes
EP0518319B1 (fr)	1999-03-24	Essai immunologique à base de liposomes pour la détection des antigènes, des anticorps et des haptènes